The Food and Drug Administration has approved a new pill designed to manage persistently high cholesterol levels. This approval introduces a more convenient option for patients who face a high risk of cardiovascular disease and heart attacks.
Unlike traditional cholesterol-lowering injections, Merck’s Lipfendra offers a daily oral alternative. This can simplify the treatment regimen for individuals struggling with high cholesterol, potentially improving adherence to prescribed therapies and overall heart health.
Increased Funding Needed for Psychiatric Hospitals 
Trump Administration Distributes ACA Refund Checks 
Higher Consumption of Ultra-Processed Foods Linked to Increased Health Risks 
Understanding Inflammation: Myths and Facts 
Calm Parenting: Strategies to Manage Stress 
Trump’s Executive Order to Combat Mosquitoes and Ticks in D.C.